Performance of capecitabine in novel combination therapies in colorectal cancer

References

• Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
   PubMed Web of Science ®Google Scholar
• Corté H, Manceau G, Blons H, Laurent-Puig P. MicroRNA and colorectal cancer. Dig Liver Dis. 2012;44(3):195–200.
   PubMedGoogle Scholar
• Eisterer W, Prager G. Chemotherapy, still an option in the twenty-first century in metastatic colorectal cancer? Cardiovasc Intervent Radiol. 2019;42(9):1213–8.
   PubMed Web of Science ®Google Scholar
• Marley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105.
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol. 2005;23(22):4866–75.
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
   PubMed Web of Science ®Google Scholar
• Johnston P, Kaye S. Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs. 2001;12(8):639–46.
   PubMed Web of Science ®Google Scholar
• Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34(8):1274–81.
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4(4):1013–9.
   PubMed Web of Science ®Google Scholar
• Morita T, Tokue A. Biomodulation of 5-fluorouracil by interferon-α in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol. 1999;44(2):91–6.
   PubMed Web of Science ®Google Scholar
• Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7(4):350–91.
   PubMed Web of Science ®Google Scholar
• Chan GH, Chee CE. Making sense of adjuvant chemotherapy in colorectal cancer. J Gastrointest Oncol. 2019;10(6):1183–92.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Barni S. 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. Med Oncol. 2012;29(2):1020–9.
   PubMed Web of Science ®Google Scholar
• Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1):197.
   PubMed Web of Science ®Google Scholar
• Di Bartolomeo M, Ciarlo A, Bertolini A, Barni S, Verusio C, Aitini E, et al. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. Eur J Cancer. 2015;51(4):473–81.
   PubMed Web of Science ®Google Scholar
• Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388–94.
   PubMed Web of Science ®Google Scholar
• Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Humbyrd C-J, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Prev Biomark. 2003;12(8):755–62.
   PubMed Web of Science ®Google Scholar
• Birkenkamp-Demtroder K, Olesen SH, Sørensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005;54(3):374–84.
   PubMed Web of Science ®Google Scholar
• Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, et al. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics J. 2018;18(5):623–32.
   PubMed Web of Science ®Google Scholar
• Kümler I, Eefsen RL, Sørensen PG, Theile S, Fullerton A, Nielsen PG, et al. An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine. Cancer Chemother Pharmacol. 2019;84(2):441–6.
   PubMed Web of Science ®Google Scholar
• Di Noia V, Basso M, Marsico V, Cerchiaro E, Rossi S, D'Argento E, et al. DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. Future Oncol. 2019;15(20):2349–60.
   PubMed Web of Science ®Google Scholar
• Xu R-H, Muro K, Morita S, Iwasa S, Han SW, Wang W, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018;19(5):660–71.
   PubMed Web of Science ®Google Scholar
• Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer. 1993;29(9):1280–4.
   Web of Science ®Google Scholar
• Lévi F, Misset J-L, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69(4):893–900.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.
   PubMed Web of Science ®Google Scholar
• Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin T-P, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57(10):1841–5.
   PubMed Web of Science ®Google Scholar
• Armand J-P, Boige V, Raymond E, Fizazi K, Faivre S. Oxaliplatin in colorectal cancer: an overview. Semin Oncol. 2000;27(5):96–104.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Hasegawa J, Kato T, Yoshioka S, Noura S, Kagawa Y, et al. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Cancer Chemother Pharmacol. 2018;82(4):707–16.
   PubMed Web of Science ®Google Scholar
• Arkenau H-T, Arnold D, Cassidy J, Diaz-Rubio E, Douillard J-Y, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]: Centre for Reviews and Dissemination (UK). 2008;26:5910–7.
   Google Scholar
• Bendell JC, Ervin TJ, Senzer NN, Richards DA, Firdaus I, Lockhart AC, et al. Results of the X-PECT study: a phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). Am Soc Clin Oncol. 2012;30(18):3501.
   PubMedGoogle Scholar
• Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012;8(5):623–33.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Nemunaitis J, Vukelja SJ, Hagenstad C, Campos LT, Hermann RC, et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second-or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2011;29(33):4394–400.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107(10):4053–62.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toft D, Ames M, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003;14(8):1169–76.
   PubMed Web of Science ®Google Scholar
• Zeynali-Moghaddam S, Mohammadian M, Kheradmand F, Fathi-Azarbayjani A, Rasmi Y, Esna-Ashari O, et al. A molecular basis for the synergy between 17-allylamino-17-demethoxy geldanamycin with capecitabine and irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression. Gene. 2019;684:30–8.
   PubMed Web of Science ®Google Scholar
• Mohammadian M, Zeynali S, Azarbaijani AF, Ansari MHK, Kheradmand F. Cytotoxic effects of the newly-developed chemotherapeutic agents 17-AAG in combination with oxaliplatin and capecitabine in colorectal cancer cell lines. Res Pharma Sci. 2017;12(6):517.
   PubMed Web of Science ®Google Scholar
• Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369(9573):1603–13.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FGR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41.
   PubMed Web of Science ®Google Scholar
• Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399–404.
   PubMed Web of Science ®Google Scholar
• Dovizio M, Tacconelli S, Sostres C, Ricciotti E, Patrignani P. Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel). 2012;5(12):1346–71.
   PubMedGoogle Scholar
• Giampieri R, Restivo A, Pusceddu V, Del Prete M, Maccaroni E, Bittoni A, et al. The role of aspirin as antitumoral agent for heavily pretreated patients with metastatic colorectal cancer receiving capecitabine monotherapy. Clin Colorectal Cancer. 2017;16(1):38–43.
   PubMed Web of Science ®Google Scholar
• Fu J, Xu Y, Yang Y, Liu Y, Ma L, Zhang Y. Aspirin suppresses chemoresistance and enhances antitumor activity of 5-Fu in 5-Fu-resistant colorectal cancer by abolishing 5-Fu-induced NF-κB activation. Sci Rep. 2019;9(1):1–11.
   PubMedGoogle Scholar
• Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946–52.
   PubMed Web of Science ®Google Scholar
• Cheng X, Xu X, Chen D, Zhao F, Wang W. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer. Biomed Pharmacother. 2019;110:473–81.
   PubMed Web of Science ®Google Scholar
• Köhne C-H, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol. 2008;19(5):920–6.
   PubMed Web of Science ®Google Scholar
• Nagore E, Insa A, Sanmartín O. Antineoplastic therapy—induced palmar plantar Erythrodysesthesia (‘Hand-Foot’) syndrome. Am J Clin Dermatol. 2000;1(4):225–34.
   PubMedGoogle Scholar
• Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006;12(3):131–41.
   PubMedGoogle Scholar
• Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, et al. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012;23(5):1348–53.
   PubMed Web of Science ®Google Scholar
• Lin EH, Kim EY, Wang L, Fong C, Shankaran V, Wu X. ADAPT therapy vs capecitabine bevacizumab in stage IV colorectal cancer: pooled 10-year survival experience and a phase II study update. Am Soc Clin Oncol. 2016;34(15):15046.
   Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30.
   PubMed Web of Science ®Google Scholar
• Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012;324(1):1–12.
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Vasse M, Körner M, Mishal Z, Ganné F, Vannier J-P, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001;22(8):1139–48.
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991;51(13):3602–9.
   PubMed Web of Science ®Google Scholar
• Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem. 1996;66(2):710–6.
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA. 1991;88(9):3628–32.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, et al. A single arm, phase II study of simvastatin plus XELOX and bevacizumab as first-line chemotherapy in metastatic colorectal cancer patients. Cancer Res Treat. 2019;51(3):1128–34.
   PubMed Web of Science ®Google Scholar
• Leung J, Brady JL, Crook MA. The clinical importance of recognizing capecitabine-induced hypertriglyceridemia: a case report and review of the literature. J Clin Lipidol. 2018;12(6):1371–3.
   PubMed Web of Science ®Google Scholar
• Manu KA, Shanmugam MK, Li F, Chen L, Siveen KS, Ahn KS, et al. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med. 2014;92(3):267–76.
   PubMed Web of Science ®Google Scholar
• Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum. 1989;18(4):282–96.
   PubMed Web of Science ®Google Scholar
• Wang W, Ho WC, Dicker DT, MacKinnon C, Winkler JD, Marmorstein R, et al. Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther. 2005;4(8):893–8.
   PubMed Web of Science ®Google Scholar
• Winer A, Denlinger CS, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, et al. First-in-human phase 1b trial of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20(1):e43–e52.
   PubMed Web of Science ®Google Scholar
• Li C, Ci Y, Liu X, Chen C, Liu C, Li X, et al. Inositol hexakisphosphate and inositol enhance the inhibition of colorectal cancer growth and liver metastasis by capecitabine in a mouse model. Nutr Cancer. 2020;73(1):1–9.
   PubMedGoogle Scholar
• Hamaguchi R, Tsuchiya T, Miyata G, Sato T, Takahashi K, Miura K, et al. Efficacy of oral administration of cystine and theanine in colorectal cancer patients undergoing capecitabine-based adjuvant chemotherapy after surgery: a multi-institutional, randomized, double-blinded, placebo-controlled, phase II trial (JORTC-CAM03). Support Care Cancer. 2020;28(8):3649–57.
   PubMed Web of Science ®Google Scholar
• Kunnumakkara AB, Diagaradjane P, Anand P, Kuzhuvelil HB, Deorukhkar A, Gelovani J, et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX‐2, MMP‐9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer. 2009;125(9):2187–97.
   PubMed Web of Science ®Google Scholar
• Huang W-Y, Cai Y-Z, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: potential use for cancer prevention. Nutr Cancer. 2009;62(1):1–20.
   Web of Science ®Google Scholar
• Lea MA, Ibeh C, Han L, Desbordes C. Inhibition of growth and induction of differentiation markers by polyphenolic molecules and histone deacetylase inhibitors in colon cancer cells. Anticancer Res. 2010;30(2):311–8.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Yasui Y, Ohigashi H, Tanaka T, Murakami A. Dietary flavonoids suppress azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Chem Biol Interact. 2010;183(2):276–83.
   PubMed Web of Science ®Google Scholar
• Spencer JP, Kuhnle GG, Williams RJ, Rice-Evans C. Intracellular metabolism and bioactivity of quercetin and its in vivo metabolites. Biochem J. 2003;372(1):173–81.
   PubMedGoogle Scholar
• Jaramillo S, Lopez S, Varela LM, Rodriguez-Arcos R, Jimenez A, Abia R, et al. The flavonol isorhamnetin exhibits cytotoxic effects on human colon cancer cells. J Agric Food Chem. 2010;58(20):10869–75.
   PubMed Web of Science ®Google Scholar
• Manu KA, Shanmugam MK, Ramachandran L, Li F, Siveen KS, Chinnathambi A, et al. Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-κB signaling cascade in gastric cancer. Cancer Lett. 2015;363(1):28–36.
   PubMed Web of Science ®Google Scholar
• Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.
   PubMed Web of Science ®Google Scholar
• Neve R, Lane H, Hynes N. The role of overexpressed HER2 in transformation. Ann Oncol. 2001;12(suppl_1):S9–S13.
   PubMedGoogle Scholar
• Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12(suppl_1):S3–S8.
   PubMedGoogle Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004;4(5):361–70.
   PubMed Web of Science ®Google Scholar
• Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312(5994):513–6.
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26(45):6469–87.
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20(1):7–12.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–23.
   PubMed Web of Science ®Google Scholar
• Ingold Heppner B, Behrens H-M, Balschun K, Haag J, Krüger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977–84.
   PubMed Web of Science ®Google Scholar
• Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73.
   PubMed Web of Science ®Google Scholar
• Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res. 2015;21(24):5519–31.
   PubMed Web of Science ®Google Scholar
• Parikh A, Atreya C, Korn WM, Venook AP. Prolonged response to HER2-directed therapy in a patient with HER2-amplified, rapidly progressive metastatic colorectal cancer. J Natl Compr Canc Netw. 2017;15(1):3–8.
   PubMed Web of Science ®Google Scholar
• Graham J, Muhsin M, Kirkpatrick P. Cetuximab. Nat Rev Drug Discov. 2004;3(7):549–50.
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301–11.
   PubMed Web of Science ®Google Scholar
• Sato Y, Hirakawa M, Ohnuma H, Takahashi M, Okamoto T, Okamoto K, et al. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study. Cancer Chemother Pharmacol. 2017;80(6):1133–9.
   PubMed Web of Science ®Google Scholar
• Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018;3(1):e000299.
   PubMed Web of Science ®Google Scholar
• Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351(2):289–305.
   PubMedGoogle Scholar
• Luu L-J, Price TJ. BRAF mutation and its importance in colorectal cancer. In: Advances in the molecular understanding of colorectal cancer. IntechOpen; 2019. p. 1–8.
   Google Scholar
• Michaloglou C, Vredeveld L, Mooi W, Peeper D. BRAF E600 in benign and malignant human tumours. Oncogene. 2008;27(7):877–95.
   PubMed Web of Science ®Google Scholar
• Mehta R. The role of HER2 testing in advanced colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(6):184–91.
   Web of Science ®Google Scholar
• Botton T, Talevich E, Mishra VK, Zhang T, Shain AH, Berquet C, et al. Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses. Cell Rep. 2019;29(3):573–88.e7.
   PubMed Web of Science ®Google Scholar
• Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann KP, et al. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer. 2015;112(6):963–70.
   PubMed Web of Science ®Google Scholar
• Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol. 2011;29(19):2675–82.
   PubMed Web of Science ®Google Scholar
• Omrcen T, Katic A, Tomic S, Eterovic D, Vrdoljak E. Predictors of outcome in elderly patients with metastatic colorectal cancer: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment. Anti-Cancer Drugs. 2020;31(5):518–22.
   PubMed Web of Science ®Google Scholar
• Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–7.
   PubMed Web of Science ®Google Scholar
• Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, et al. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS-and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol. 2019;10(2):304–10.
   PubMed Web of Science ®Google Scholar
• Wei L, Chen J, Wen J, Wu D, Ma X, Chen Z, et al. Efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer. Med Sci Monit. 2020;26:e919031.
   PubMed Web of Science ®Google Scholar
• Su J, Lai J, Yang R, Xu B, Zhu Y, Zhao M, et al. Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women. BMC Gastroenterol. 2019;19(1):17.
   PubMedGoogle Scholar
• Papaxoinis G, Kotoula V, Giannoulatou E, Koliou G-A, Karavasilis V, Lakis S, et al. Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Med Oncol. 2018;35(7):101.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077–85.
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28(19):3191–8.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.
   PubMed Web of Science ®Google Scholar
• Matsui T, Nagata N, Hirata K, Okazaki S, Sato S, Nakamura M, et al. Bi-weekly capecitabine–oxaliplatin (XELOX) plus bevacizumab as first-line treatment of metastatic colorectal cancer–the PHOENiX trial. Anticancer Res. 2016;36(7):3437–43.
   PubMed Web of Science ®Google Scholar
• Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, et al. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Dev Ther. 2015;9:1653.
   Google Scholar
• Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, et al. Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer. 2015;15(1):327.
   PubMedGoogle Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–8.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, et al. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. BMC Cancer. 2019;19(1):1–9.
   PubMed Web of Science ®Google Scholar
• Estécio MR, Issa J-PJ. Dissecting DNA hypermethylation in cancer. FEBS Lett. 2011;585(13):2078–86.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, et al. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016;7(41):67495–506.
   PubMedGoogle Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2(12):1125–31.
   PubMed Web of Science ®Google Scholar
• Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, et al. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol. 2019;10(3):412–20.
   PubMed Web of Science ®Google Scholar
• Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev. 2014;33(4):1095–108.
   PubMed Web of Science ®Google Scholar
• Sennoune SR, Luo D, Martinez-Zaguilán R. Plasmalemmal vacuolar-type H+-ATPase in cancer biology. CBB. 2004;40(2):185–206.
   Google Scholar
• Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702–13.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Baldi A, Buglioni S, Carocci F, Milesi de Bazzichini G, Betti G, et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med. 2011;9(1):221– 12.
   PubMedGoogle Scholar
• McLeod HL, Evans WE. Oral cancer chemotherapy: the promise and the pitfalls. Clin Cancer Res. 1999;5(10):2669–71.
   PubMed Web of Science ®Google Scholar
• Rotermann M, Sanmartin C, Hennessy D, Arthur M. Prescription medication use by Canadians aged 6 to 79. Health Rep. 2014;25(6):3–9.
   Web of Science ®Google Scholar
• Van Cutsem E, Verslype C, Tejpar S. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. Semin Oncol. 2005;32(1):43–51.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, et al. Oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol. 2003;14(12):1735–43.
   PubMed Web of Science ®Google Scholar
• Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, et al. Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer. 2016;15(3):257–63.
   PubMed Web of Science ®Google Scholar
• Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, et al. Effects of proton pump inhibitors on FOLFOX and CapeOx regimens in colorectal cancer. Clin Colorectal Cancer. 2019;18(1):72–9.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097–106.
   PubMed Web of Science ®Google Scholar
• Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24(3):457–61.
   PubMed Web of Science ®Google Scholar
• Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand–foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002;20(1):3–10.
   PubMed Web of Science ®Google Scholar
• Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med. 1984;101(6):798–800.
   PubMed Web of Science ®Google Scholar
• Elif A, Yucel KT, Ekincioglu AB, Gullu I. Capecitabine induced hand-foot syndrome: a systematic review of case reports. Clin Exp Health Sci. 2019;9(2):178–91.
   Web of Science ®Google Scholar
• Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park, NY). 2004;18(9):1161–8; discussion 73.
   PubMed Web of Science ®Google Scholar
• Alsaloumi L, Shawagfeh S, Abdi A, Basgut B. Efficacy and safety of capecitabine alone or in combination in advanced metastatic breast cancer patients previously treated with anthracycline and taxane: a systematic review and meta-analysis. Oncol Res Treat. 2020;43(12):694–9.
   PubMed Web of Science ®Google Scholar
• Palaniappan M, Srinivasamurthy S, Dubashi B, Chandrasekaran A. Anticancer drug induced palmar plantar erythrodysesthesia. J Clin Diagn Res. 2014;8(10):HC01.
   PubMedGoogle Scholar
• Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 2004;94(2):320–4.
   PubMed Web of Science ®Google Scholar
• Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park, NY). 2002;16(12 Suppl No 14):31–7.
   PubMed Web of Science ®Google Scholar
• Kara IO, Sahin B, Erkisi M. Palmar–plantar erythrodysesthesia due to docetaxel–capecitabine therapy is treated with vitamin E without dose reduction. Breast. 2006;15(3):413–23.
   Web of Science ®Google Scholar
• Nikolaou V, Syrigos K, Saif M. Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf. 2016;15(12):1625–33.
   PubMed Web of Science ®Google Scholar
• Yamamoto D, Yamamoto C, Tanaka K. Novel and effective management of capecitabine induced hand foot syndrome. J Clin Oncol. 2008;26(15_suppl):20615.
   Web of Science ®Google Scholar
• Richards DM, Ross WA. Gastrointestinal bleeding in critically ill cancer patients: causes and management. Oncol Crit Care. 2020:857–67.
   Google Scholar
• Motl S. Bevacizumab in combination chemotherapy for colorectal and other cancers. Am J Health Syst Pharm. 2005;62(10):1021–32.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr U-P. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol. 2010;136(5):737–43.
   PubMed Web of Science ®Google Scholar
• Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015;21(17):5158.
   PubMed Web of Science ®Google Scholar